{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:05:54Z","timestamp":1792710354525,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.resinv.2022.03.004","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T23:39:48Z","timestamp":1649979588000},"page":"503-509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Current perspective of progressive-fibrosing interstitial lung disease"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3335-5409","authenticated-orcid":false,"given":"Tomoo","family":"Kishaba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.resinv.2022.03.004_bib1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S0140-6736(21)01826-2","article-title":"Treatment of fibrotic interstitial lung disease: current approaches and future directions","volume":"Oct","author":"Johannson","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2022.03.004_bib2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.chest.2021.02.021","article-title":"Identification and remediation of environmental exposures in patients with interstitial lung disease: evidence review and practical considerations","volume":"160","author":"Copeland","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2022.03.004_bib3","doi-asserted-by":"crossref","first-page":"208219","DOI":"10.1155\/2011\/208219","article-title":"Blocking TGF\u03b2 via inhibition of the \u03b1v\u03b26 integrin: a possible therapy for systemic sclerosis interstitial lung disease","volume":"2011","author":"Katsumoto","year":"2011","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.resinv.2022.03.004_bib4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/MCP.0000000000000810","article-title":"Biopsy in interstitial lung disease:\u00a0specific diagnosis and the identification of the progressive fibrotic phenotype","volume":"27","author":"Ravaglia","year":"2021","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.resinv.2022.03.004_bib5","doi-asserted-by":"crossref","first-page":"107608","DOI":"10.1016\/j.intimp.2021.107608","article-title":"Inflammatory mediators in various molecular pathways involved in the development of pulmonary fibrosis","volume":"96","author":"Fathimath Muneesa","year":"2021","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.resinv.2022.03.004_bib6","article-title":"Transbronchial biopsy in chronic hypersensitivity pneumonitis","volume":"38","author":"Botelho","year":"2021","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.resinv.2022.03.004_bib7","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1159\/000517921","article-title":"Prognostic implication of diagnostic confidence level in patients with fibrotic hypersensitivity pneumonitis","volume":"100","author":"Kang","year":"2021","journal-title":"Respiration"},{"key":"10.1016\/j.resinv.2022.03.004_bib8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1164\/rccm.200912-1855OC","article-title":"Gene set analysis of lung samples provides\u00a0insight into pathogenesis of progressive, fibrotic pulmonary sarcoidosis","volume":"181","author":"Lockstone","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2022.03.004_bib9","first-page":"99","article-title":"The right upper lobe bronchus angle: a tool for differentiating fibrotic and non-fibrotic sarcoidosis","volume":"37","author":"Salvatore","year":"2020","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.resinv.2022.03.004_bib10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12890-021-01608-1","article-title":"Efficacy of treatment with corticosteroids for\u00a0fibrotic hypersensitivity pneumonitis: a propensity score-matched cohort analysis","volume":"21","author":"Ejima","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2022.03.004_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-3-030-68748-9_5","article-title":"Interstitial lung disease associated with connective tissue diseases","volume":"1304","author":"Peredo","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.resinv.2022.03.004_bib12","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/1744666X.2021.1968832","article-title":"An IPF-like disease course in disorders other than IPF: how can this be anticipated, recognized, and managed?","volume":"17","author":"Wells","year":"2021","journal-title":"Expet Rev Clin Immunol"},{"key":"10.1016\/j.resinv.2022.03.004_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2017-000212","article-title":"Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease","volume":"4","author":"Flaherty","year":"2017","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.resinv.2022.03.004_bib14","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"INBUILD trial investigators. Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2022.03.004_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/14397595.2020.1826665","article-title":"Progressive fibrosing interstitial lung diseases: a new concept and indication of nintedanib","volume":"31","author":"Makino","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2022.03.004_bib16","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1159\/000509556","article-title":"Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers","volume":"99","author":"Faverio","year":"2020","journal-title":"Respiration"},{"key":"10.1016\/j.resinv.2022.03.004_bib17","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3390\/jcm10112285","article-title":"Antifibrotic therapies and progressive fibrosing interstitial lung disease (PF-ILD): building on INBUILD","volume":"25","author":"Shumar","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.resinv.2022.03.004_bib18","doi-asserted-by":"crossref","first-page":"2100221","DOI":"10.1183\/13993003.00221-2021","article-title":"The burden of progressive fibrotic interstitial lung disease across the UK","volume":"58","author":"Simpson","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2022.03.004_bib19","doi-asserted-by":"crossref","first-page":"2000085","DOI":"10.1183\/13993003.00085-2020","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"55","author":"Brown","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2022.03.004_bib20","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1007\/s10067-021-05693-9","article-title":"Evaluation of rheumatoid arthritis and connective tissue disease-related interstitial lung disease with pulmonary physiologic test, HRCT, and patient-based measures of dyspnea and functional disability","volume":"40","author":"Topcu","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resinv.2022.03.004_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/1573397116666200905122757","article-title":"Pulmonary manifestations of rheumatoid arthritis, psoriatic arthritis and peripheral spondyloarthritis: prevalence, diagnostic approach and treatment options","volume":"17","author":"Dejcman","year":"2021","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.resinv.2022.03.004_bib22","article-title":"Pharmacological and nonpharmacological interventions to improve symptom control, functional exercise capacity and quality of life in interstitial lung disease: an evidence synthesis","volume":"25","author":"Bajwah","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resinv.2022.03.004_bib23","first-page":"1","article-title":"Patient Activation for self-management in patients with idiopathic pulmonary fibrosis or sarcoidosis","volume":"31","author":"Bloem","year":"2021","journal-title":"Respiration"},{"key":"10.1016\/j.resinv.2022.03.004_bib24","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1007\/s10067-019-04720-0","article-title":"Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases","volume":"38","author":"Fischer","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resinv.2022.03.004_bib25","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2022.03.004_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025322","article-title":"Clinical characteristics of non-idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung diseases: a single-center retrospective study","volume":"100","author":"Komatsu","year":"2021","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.resinv.2022.03.004_bib27","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/resp.12360","article-title":"Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease","volume":"19","author":"Holland","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2022.03.004_bib28","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.21037\/jtd.2016.03.89","article-title":"Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status","volume":"8","author":"Kishaba","year":"2016","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.resinv.2022.03.004_bib29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ebiom.2019.10.050","article-title":"A. Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease","volume":"50","author":"Hoffmann-Vold","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.resinv.2022.03.004_bib30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.200611-1696OC","article-title":"Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival","volume":"177","author":"Sumikawa","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2022.03.004_bib31","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.3390\/jcm10173806","article-title":"Decision-making strategy for the treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD)","volume":"10","author":"Yamakawa","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.resinv.2022.03.004_bib32","doi-asserted-by":"crossref","first-page":"708","DOI":"10.12659\/MSM.890880","article-title":"A retrospective study of clinical characteristics of interstitial lung disease associated with rheumatoid arthritis in Chinese patients","volume":"21","author":"Wang","year":"2015","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.resinv.2022.03.004_bib33","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s40744-021-00362-4","article-title":"A closer look at the role of anti-CCP antibodies in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and bronchiectasis","volume":"8","author":"Khan","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.resinv.2022.03.004_bib34","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2022.03.004_bib35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12931-021-01817-6","article-title":"Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States","volume":"22","author":"Aronson","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2022.03.004_bib36","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12931-021-01879-6","article-title":"Progressive fibrosing interstitial lung disease: prevalence and clinical outcome","volume":"22","author":"Kwon","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2022.03.004_bib37","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.3390\/jcm10143167","article-title":"M. Serum biomarkers in differential diagnosis of idiopathic pulmonary fibrosis and connective tissue disease-associated interstitial lung disease","volume":"10","author":"Cabrera Cesar","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.resinv.2022.03.004_bib38","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/annrheumdis-2019-216694","article-title":"Is the epidemiology of rheumatoid arthritis changing? results from a population-based incidence study, 1985-2014","volume":"79","author":"Myasoedova","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2022.03.004_bib39","doi-asserted-by":"crossref","first-page":"100119","DOI":"10.1016\/j.jtauto.2021.100119","article-title":"Causal risk and protective factors in rheumatoid arthritis: a genetic update","volume":"4","author":"Arleevskaya","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.resinv.2022.03.004_bib40","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jbspin.2019.12.006","article-title":"Bronchiectasis in rheumatoid arthritis. A clinical appraisial","volume":"87","author":"Duarte","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.resinv.2022.03.004_bib41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12890-021-01569-5","article-title":"Fet\u00a0al. Mortality rate in rheumatoid arthritis-related interstitial lung disease: the role of radiographic patterns","volume":"21","author":"Nieto","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2022.03.004_bib42","doi-asserted-by":"crossref","first-page":"210011","DOI":"10.1183\/16000617.0011-2021","article-title":"Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management","volume":"30","author":"Kadura","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resinv.2022.03.004_bib43","doi-asserted-by":"crossref","DOI":"10.1007\/s12016-021-08891-0","article-title":"Therapeutic approaches to systemic sclerosis: recent approvals and future candidate therapies","author":"Lescoat","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.resinv.2022.03.004_bib44","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11547-018-0894-3","article-title":"Relationship between interstitial lung disease and oesophageal dilatation on chest high-resolution computed tomography in patients with systemic sclerosis: a cross-sectional study","volume":"123","author":"Salaffi","year":"2018","journal-title":"Radiol Med"},{"issue":"7","key":"10.1016\/j.resinv.2022.03.004_bib45","article-title":"Demographic and lifestyle risk factors for gastroesophageal reflux disease and Barrett\u2019s esophagus in Australia","volume":"Jan","author":"Wang","year":"2022","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.resinv.2022.03.004_bib46","first-page":"195","article-title":"Radiologic and pathologic characteristics of myeloperoxidase-antineutrophil cytoplasmic antibody-associated interstitial lung disease: a retrospective analysis","volume":"36","author":"Baqir","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"24","key":"10.1016\/j.resinv.2022.03.004_bib47","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/1756-185X.14213","article-title":"Myeloperoxidase and associated lung disease: review of the latest developments","volume":"Dec","author":"Hu","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.resinv.2022.03.004_bib48","doi-asserted-by":"crossref","first-page":"e13565","DOI":"10.14814\/phy2.13565","article-title":"The influence of pulmonary vascular pressures on lung diffusing capacity during incremental exercise in healthy aging","volume":"6","author":"Coffman","year":"2018","journal-title":"Physiol Rep"},{"key":"10.1016\/j.resinv.2022.03.004_bib49","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/resp.12763","article-title":"Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis","volume":"21","author":"Hosoda","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2022.03.004_bib50","doi-asserted-by":"crossref","first-page":"102338","DOI":"10.1016\/j.jaut.2019.102338","article-title":"Usual interstitial pneumonia in ANCA-associated vasculitis: a poor prognostic factor","volume":"106","author":"Maillet","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.resinv.2022.03.004_bib51","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1164\/rccm.202005-2032ST","article-title":"Diagnosis of hypersensitivity pneumonitis in adults. An official ATS\/JRS\/ALAT clinical practice guideline","volume":"202","author":"Raghu","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2022.03.004_bib52","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4046\/trd.2020.0122","article-title":"Role of Krebs von den Lungen-6 (KL-6) in Assessing Hypersensitivity Pneumonitis","volume":"84","author":"Mostafa","year":"2021","journal-title":"Tuberc Respir Dis"},{"key":"10.1016\/j.resinv.2022.03.004_bib53","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3390\/jcm9010142","article-title":"Computed tomography images of fibrotic pulmonary sarcoidosis leading to chronic respiratory failure","volume":"9","author":"Sawahata","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.resinv.2022.03.004_bib54","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1513\/AnnalsATS.201303-069FR","article-title":"Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes","volume":"10","author":"Patterson","year":"2013","journal-title":"Ann Am Thorac Soc."},{"key":"10.1016\/j.resinv.2022.03.004_bib55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4046\/trd.2019.0009","article-title":"Korean interstitial lung diseases study group. Korean guidelines for diagnosis and management of interstitial lung diseases: Part 5. Connective tissue disease associated interstitial lung disease","volume":"82","author":"Koo","year":"2019","journal-title":"Tuberc Respir Dis"},{"key":"10.1016\/j.resinv.2022.03.004_bib56","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2022.03.004_bib57","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"RELIEF investigators. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2022.03.004_bib58","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2022.03.004_bib59","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"SENSCIS trial investigators. Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2022.03.004_bib60","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"NBUILD trial investigators. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534522000296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534522000296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:32:08Z","timestamp":1761949928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534522000296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2212534522000296"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2022.03.004","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current perspective of progressive-fibrosing interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2022.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}